Loading...
Loading...
In a research report published today, Morgan Stanley said Medicis Pharmaceutical's
MRX 4Q results included operating margin upside partially offset by an unusually high tax rate.
According to Morgan Stanley, “Revenues were $181M, in line with our $179M and cons' $180M. EPS were $0.56, 5% above our $0.53 and cons' $0.55. Note MRX excluded $8.9M amort. expense (both original MRX amort + new Graceway amort.) from non-GAAP EPS (as planned). Operating margin was
36.6% vs. our 29.8% estimate. Tax rate was 49.4% vs. our 39.5% estimate due to one-time Graceway acq. taxes.”
Morgan Stanley maintains its Equal-weight rating on Medicis Pharmaceuticals, which closed yesterday at $33.81.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in